Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of DOAC anticoagulation after thrombectomy for ischemic stroke with atrial fibrillation (Trial-1)
ChiCTR2500108184Phase 3Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Draxaban in ischemic stroke, Atrial fibrillation (AFib), venous thromboembolism (VTE) and 1 more (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Composite outcome of recurrent ischemic stroke, symptomatic intracranial hemorrhage, and all-cause death. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Draxaban
03
Conditions
ischemic strokeAtrial fibrillation (AFib)venous thromboembolism (VTE)systemic embolism
Beyond the preview
Go deeper on ChiCTR2500108184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108184.